Obesity (Disorder)BARIMOVNCT07663942
Targeting Sedentary Behavior Reduction and Physical Fitness Enhancement in Women Before and Beyond Bariatric Surgery- BARIMOV Study Protocol
A study testing Sedentary behavior reduction program on physical fitness. in people with Obesity (Disorder), run by Hospital de Sao Sebastiao at 1 site in Portugal.
Trial summary
Introduction: Sedentary behavior (SB) and insufficient physical activity (PA) interact to worsen physical fitness (PF), obesity-related complications and diseases (ORCD), and all-cause mortality in women with obesity. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Obesity (Disorder)
- What is being tested?
- Sedentary behavior reduction program on physical fitness.
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 72 participants
- Where
- 1 sitePortugal
- Study dates
- 20 Apr 2026to 20 Apr 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult women (≥ 18 years);
- BMI of 30-45 kg/m2;
- Scheduled for primary vertical sleeve gastrectomy or Roux-en-Y gastric bypass;
- Capacity to provide informed consent, adequate proficiency in the national language;
- Access to the internet and mobile phone communication.
Who cannot join
- Previous bariatric surgery or gastric surgical procedure;
- Physical incapacity or medical contraindications precluding physical fitness testing or participation (active cardiac disease, uncontrolled hypertension, severe joint disease);
- Pregnancy or breastfeeding;
- Inability to provide informed consent or comply with study procedures;
- Patients with type 1 or 2 diabetes mellitus.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Portugal1 site, 1 recruiting
- Recruiting
Unidade Local de Saúde de Entre Douro e Vouga
Santa Maria da Feira, 4520-211
Unidade Local de Saúde de Entre Douro e Vouga, +351 256 379 700, geral@ulsedv.min-saude.pt
Marta Guimarães
About this study
Introduction: Sedentary behavior (SB) and insufficient physical activity (PA) interact to worsen physical fitness (PF), obesity-related complications and diseases (ORCD), and all-cause mortality in women with obesity. Replacing SB with low-intensity PA may improve PF and ameliorate ORCD, with potential lasting effects after bariatric surgery (BS). However, strong evidence on how PF influences BS outcomes and whether preoperative PA interventions can improve postoperative outcomes is lacking. The BARIMOV study aims to evaluate the effects of a structured sedentary behavior reduction program (SBRPro) on PF, investigate whether PF improvements influence BS outcomes, and explore potential mechanistic pathways by characterizing molecular adaptations in peripheral blood, skeletal muscle, and visceral adipose tissue (VAT).
Methods: BARIMOV is a prospective cohort study with five assessment time points. Adult women (≥18 years) with BMI 30-45 kg/m² scheduled for BS will be recruited (n = 72). At T0, participants will undergo a baseline assessment of PF - body composition, muscle strength, cardiorespiratory fitness - PA patterns, and ORCD screening. Participants will be instructed in the SBRPro and asked to maintain weekly PA diaries throughout the pre- and post-operative periods. At T1, adherence to SBRPro will be evaluated via diary review and PF reassessment, to enable participants' allocation into two adherence-based groups. At T2, during surgery, skeletal muscle and VAT biopsies will be collected for proteomic analysis to compare molecular adaptations of adherent and non-adherent groups. At T3 and T4, primary outcomes, including weight loss, body composition, ORCD, and quality of life (QoL), will be evaluated at 3±1 and 12±1 months postoperatively, respectively. Blood multiomics profiling will be performed at T0, T1, and T3 to explore dynamic changes in systemic metabolic pathways over time.
Conclusion: This study will determine whether PF improvement, achieved through structured SB reduction and PA engagement, is associated with better BS outcomes. By integrating clinical and molecular endpoints, the study will provide mechanistic insights into the pathways by which PF enhances BS outcomes and inform physical activity intervention strategies.
Read the detailed description
- Study Design and Participants BARIMOV will be a prospective cohort study designed to evaluate the effects of an SBRPro on BS outcomes in women and to explore the biological mechanisms underlying these effects. The study includes five predefined assessment timepoints: baseline (T0, 6±3 months before surgery), preoperative reassessment (T1, 2 weeks±3 days before surgery), intraoperative biopsies (T2), early postoperative reassessment (T3, 3±1 months after surgery), and final postoperative reassessment (T4, 12±2 months after surgery).
- Intervention Participants will be instructed to follow an online SBRPro program initiated 6±3 months before surgery. SBRPro provides standardized guidance on decreasing sedentary time and increasing regular PA, tailored to individual capabilities, delivered via mobile phone apps featuring messages, videos, and PA and exercise tutorials. The intervention will comprise 3 main phases.
Phase 1: Enrollment and Multidisciplinary Education (T0) All participants will attend a group educational session (40 minutes) delivered by a multidisciplinary team (bariatric surgeon, exercise physiologist, dietitian) addressing: 1) overall education about the BS clinical process and surgery procedures, risks, advantages and disadvantages; 2) a comprehensive education on SB harms and health risks, and benefits of PA across the pre- and post-operative period; 3) practical strategies for reducing sedentary time (e.g., breaking up prolonged sitting or interrupting extended bouts); 4) PA safety, proper exercise execution, PA intensity management and progression strategies; 5) nutritional education for preoperative fitness and postoperative recovery; and 6) distribution of written materials (flyers and booklets) summarizing key take home contents delivered at the session.
Phase 2: Structured Preoperative Sedentary Behavior Reduction Program (T0 to T1) Participants will be asked to engage in the SBRPro, which includes aerobic and strength activities, in compliance with current PA guidelines. Flexibility to adapt the PA and exercise modality, duration, and intensity based on individual preferences, physical capacity, and available resources (home-based, gym-based, online platforms, or combined approaches) will be provided.
Phase 3: Structured Postoperative Sedentary Behavior Reduction Program (T2 to T4) Participants will be asked to resume SBRPro activities within the first week post-BS, adjusting the program for postoperative individual restrictions. A progressive increase in daily PA will be encouraged. For resistance exercises, participants will be advised to avoid heavy loading of incision/staple lines and to progress from light to moderate resistance as tolerated. Given the postoperative vulnerability, remote counseling will be provided as needed to enhance safety. The same weekly PA diary-based monitoring will be requested.
Physical Activity Monitoring and Adherence Assessment SBRPro adherence will be assessed through a structured weekly PA diary using a simple online form. The form will collect self-reported data on average daily sedentary time (minutes per day), total time spent in light, moderate, and vigorous physical activity (minutes per week), and the number of days per week engaged in resistance training. The form will also include a subsection addressing PA satisfaction/enjoyment (5-point Likert scale: 1, nothing fun; 2, little fun; 3, indifferent; 4, fun; 5, very fun), and any barriers or adverse events encountered. This weekly assessment will take place from baseline (the moment of enrolment in the study) until up to 12 months after surgery. For primary analyses, adherence subgroups, determined from the weekly PA diary, will be classified as having either an active or a sedentary lifestyle according to the most recent World Health Organization criteria. Individuals will be classified as physically active if they accumulate at least 150 minutes of moderate-intensity physical activity per week, and as sedentary if they do not meet this threshold. Participants with a sedentary lifestyle will serve as the de facto comparison group. This will enable evaluation of whether differential engagement with the SBRPro is associated with distinct clinical and functional outcomes.
- Clinical and Functional Assessments PF evaluations that include changes in body composition, muscle strength, and CRF will be assessed to determine the effects of the SBRPro. Body composition [total weight (kg) and weight loss (absolute and % excess weight lost), fat mass (kg and %), lean mass (kg and %), muscle mass (kg and %)] will be measured via bioimpedance analysis (InBody 970 model, Biospace, Korea). Muscle strength (Kgf) will be assessed using handgrip (Jamar+, Lafayette Instrument Company, USA) and knee isometric strength tests (GripWise, Wisify Tech Solutions, Lda., Portugal). The estimated CRF (eVO2m) will be evaluated using the 2-minute step test (2MST). Changes in PA patterns between T0 and T1, and T2 and T3 will be subjectively measured using the language validated 24-hour movement questionnaire (QMov24h) and objectively measured PA, between T1 and T2, via accelerometry (ActiGraph wGT3X-BT model, Ametrics, USA), worn for 7 days, quantifying daily activity volume (steps, minutes of light, moderate, and vigorous activity), and sedentary time. The resolution or improvement of the ORCD and the health-related QoL will be assessed using the SF-12 (12-item Short Form Health Survey) validated questionnaire.
- Biological Sampling and Molecular Analyses Fasting blood samples will be collected at T0, T1, and T3. Plasma will be processed and stored at -80ºC for metabolomic profiling. Circulating metabolomic profiling will be performed using proton nuclear magnetic resonance (1H-NMR) spectroscopy to evaluate longitudinal systemic metabolic adaptations across time points. Molecular findings will subsequently be integrated with clinical and functional outcomes to explore potential mechanistic links between behavioral modification, tissue remodeling, and postoperative results.
During BS (T2), biopsies of abdominal skeletal muscle (transversus abdominis) and visceral adipose tissue (VAT) will be obtained under direct surgical visualization. Tissue fragments will be immediately processed and preserved at -80ºC for downstream proteomic analysis. Label-free quantitative proteomics, using the GeLC MS/MS approach, will be performed to identify differential protein expression patterns between adherence groups. Functional enrichment and pathway analyses will be conducted to characterize biological processes associated with preoperative SB reduction and PA engagement.
- Conditions
- Obesity (Disorder)
- Being tested
- Sedentary behavior reduction program on physical fitness.
- Keywords
- physical inactivity, weight loss, quality of life, adiposity, skeletal muscle, adipose tissue
- Medical subject headings
- Obesity, Sedentary Behavior, Weight Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sedentary behavior reduction program on physical fitness.Behavioural
The BARIMOV protocol incorporates this evidence through a structured, online sedentary behavior reduction program (SBRPro) that emphasizes substituting sedentary behavior with physical activity throughout the day.
| Study group | Role | What they receive |
|---|---|---|
| Adherent group | Experimental | Participants will be instructed in the sedentary behavior reduction program (SBRPro) and asked to maintain weekly physical activity diaries throughout the pre- and post-operative periods. Receives: Behavioral: Sedentary behavior reduction program on physical fitness. |
| Non-adherent group | No intervention | Non-adherence to the sedentary behavior reduction program. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of total weight loss (%TWL)
Primary clinical outcome evaluating the percentage of total weight loss, measuring weight in kilograms before and after surgery.
Measured: Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Obesity-related complications and diseases (ORCD)
Pre- and post-operative status comparison through in-person clinical evaluations and routine laboratory analyses, including physical examination findings and longitudinal changes in pharmacological treatment requirements. ORCD will be assessed as a composite outcome including the presence of the following conditions, defined using a standardized criterion: Type 2 diabetes mellitus: HbA1c≥6.5% or use of glucose-lowering medication; Hypertension: systolic BP≥140 mmHg, diastolic BP≥90 mmHg, or antihypertensive treatment; Dyslipidemia: LDL-C, HDL-C, or triglycerides outside guideline thresholds or lipid-lowering therapy; Obstructive sleep apnea: confirmed by polysomnography [AHI≥5 events/hour]; Gastroesophageal reflux disease (GERD): heartburn and/or acid regurgitation occurring≥2 times per week or current use of proton pump inhibitors (PPIs) for reflux symptoms with prior physician diagnosis of GERD; Metabolic syndrome: defined according to NCEP ATP ΙΙΙ criteria.
Measured: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Changes in health-related quality of life (QoL)
Primary clinical outcome assessed by using the SF-12 (12-item Short Form Health Survey), a validated questionnaire.
Measured: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Secondary outcomes (5)
Body composition
Body composition [fat mass (in kilograms and percentage), lean mass (in kilograms and percentage), muscle mass (in kilograms and percentage)], measured via bioimpedance analysis (InBody 970 model, Biospace, Korea), will be combined to report the complete assessment of body composition.
Measured: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Muscle strength
Muscle strength (Kgf) will be assessed using handgrip (Jamar+, Lafayette Instrument Company, USA) and knee isometric strength tests (GripWise, Wisify Tech Solutions, Lda., Portugal). The handgrip strength evaluation method follows the Southampton protocol. Participants perform three trials in each hand (alternating sides), and the maximal grip score will be used. Assessment of isometric knee extensor strength will be performed with participants seated. The test involves three maximal voluntary isometric contractions. Participants will be instructed to hold the side of the plinth for stabilization. Constant verbal encouragement will be provided throughout the testing. A submaximal practice trial is performed for each leg to ensure the participant understands the required contraction. Three trials will be recorded for each knee, and the maximal strength value will be used.
Measured: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Cardiorespiratory fitness (CRF)
The estimated CRF (ml/min/kg) will be evaluated using the 2-minute step test (2MST). Briefly, the 2MST will be performed using a single, portable step that is 15 cm high. Participants are instructed to go up and down the step as many times as possible for two minutes (free cadence). The evaluator is responsible for counting up-and-down step cycles (UDS). The test will be performed according to the recommendations of the American Thoracic Society.
Measured: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Identification of proteomic differences in skeletal muscle and visceral adipose tissue associated with adherence at the time of surgery
Tissue fragments will be immediately processed and preserved at -80 ºC for downstream proteomic analysis. Label-free quantitative proteomics, using the GeLC MS/MS approach, will be performed to identify differential protein expression patterns between adherence groups.
Measured: Intra-operative: T2
Longitudinal blood metabolomic adaptations
Plasma will be processed and stored at -80 ºC for metabolomic profiling. Circulating metabolomic profiling will be performed using proton nuclear magnetic resonance (1H-NMR) spectroscopy to evaluate longitudinal systemic metabolic adaptations across time points.
Measured: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2026
- Study start20 Apr 2026
- Primary completion20 Oct 2030 (estimated)
- Study completion20 Apr 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity (Disorder)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 72 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital de Sao Sebastiao
- Sponsor type
- University, hospital or other
- Collaborators
- Universidade Lusófona - Centro Universitário do Porto, Unidade Multidisciplinar de Investigação Biomédica, Universidade do Porto, COFAC Cooperativa de Formacao e Animacao Cultural CRL (Portugal)
- Responsible party
- Principal investigator, Marta Guimarães, Hospital de Sao Sebastiao
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07663942
- Sponsor's protocol ID
- ULSEDV
- Acronym
- BARIMOV
- Status last verified
- Jun 2026
- First submitted
- 22 Apr 2026
- Last updated
- 23 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Targeting Sedentary Behavior Reduction and Physical Fitness Enhancement in Women Before and Beyond Bariatric Surgery- BARIMOV Study Protocol
- ClinicalTrials.gov ID
- NCT07663942
- Acronym / sponsor ID
- BARIMOV / ULSEDV
- Conditions
- Obesity (Disorder)
- Keywords
- physical inactivity, weight loss, quality of life, adiposity, skeletal muscle, adipose tissue
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 72 participants (estimated)
- Lead sponsor
- Hospital de Sao SebastiaoUniversity, hospital or other
- Collaborators
- Universidade Lusófona - Centro Universitário do Porto, Unidade Multidisciplinar de Investigação Biomédica, Universidade do Porto, COFAC Cooperativa de Formacao e Animacao Cultural CRL (Portugal)
- Study start
- 20 Apr 2026 (actual)
- Primary completion
- 20 Oct 2030 (estimated)
- Study completion
- 20 Apr 2031 (estimated)
- First posted
- 23 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction: Sedentary behavior (SB) and insufficient physical activity (PA) interact to worsen physical fitness (PF), obesity-related complications and diseases (ORCD), and all-cause mortality in women with obesity. Replacing SB with low-intensity PA may improve PF and ameliorate ORCD, with potential lasting effects after bariatric surgery (BS). However, strong evidence on how PF influences BS outcomes and whether preoperative PA interventions can improve postoperative outcomes is lacking. The BARIMOV study aims to evaluate the effects of a structured sedentary behavior reduction program (SBRPro) on PF, investigate whether PF improvements influence BS outcomes, and explore potential mechanistic pathways by characterizing molecular adaptations in peripheral blood, skeletal muscle, and visceral adipose tissue (VAT).
Methods: BARIMOV is a prospective cohort study with five assessment time points. Adult women (≥18 years) with BMI 30-45 kg/m² scheduled for BS will be recruited (n = 72). At T0, participants will undergo a baseline assessment of PF - body composition, muscle strength, cardiorespiratory fitness - PA patterns, and ORCD screening. Participants will be instructed in the SBRPro and asked to maintain weekly PA diaries throughout the pre- and post-operative periods. At T1, adherence to SBRPro will be evaluated via diary review and PF reassessment, to enable participants' allocation into two adherence-based groups. At T2, during surgery, skeletal muscle and VAT biopsies will be collected for proteomic analysis to compare molecular adaptations of adherent and non-adherent groups. At T3 and T4, primary outcomes, including weight loss, body composition, ORCD, and quality of life (QoL), will be evaluated at 3±1 and 12±1 months postoperatively, respectively. Blood multiomics profiling will be performed at T0, T1, and T3 to explore dynamic changes in systemic metabolic pathways over time.
Conclusion: This study will determine whether PF improvement, achieved through structured SB reduction and PA engagement, is associated with better BS outcomes. By integrating clinical and molecular endpoints, the study will provide mechanistic insights into the pathways by which PF enhances BS outcomes and inform physical activity intervention strategies.
Detailed description
- Study Design and Participants BARIMOV will be a prospective cohort study designed to evaluate the effects of an SBRPro on BS outcomes in women and to explore the biological mechanisms underlying these effects. The study includes five predefined assessment timepoints: baseline (T0, 6±3 months before surgery), preoperative reassessment (T1, 2 weeks±3 days before surgery), intraoperative biopsies (T2), early postoperative reassessment (T3, 3±1 months after surgery), and final postoperative reassessment (T4, 12±2 months after surgery).
- Intervention Participants will be instructed to follow an online SBRPro program initiated 6±3 months before surgery. SBRPro provides standardized guidance on decreasing sedentary time and increasing regular PA, tailored to individual capabilities, delivered via mobile phone apps featuring messages, videos, and PA and exercise tutorials. The intervention will comprise 3 main phases.
Phase 1: Enrollment and Multidisciplinary Education (T0) All participants will attend a group educational session (40 minutes) delivered by a multidisciplinary team (bariatric surgeon, exercise physiologist, dietitian) addressing: 1) overall education about the BS clinical process and surgery procedures, risks, advantages and disadvantages; 2) a comprehensive education on SB harms and health risks, and benefits of PA across the pre- and post-operative period; 3) practical strategies for reducing sedentary time (e.g., breaking up prolonged sitting or interrupting extended bouts); 4) PA safety, proper exercise execution, PA intensity management and progression strategies; 5) nutritional education for preoperative fitness and postoperative recovery; and 6) distribution of written materials (flyers and booklets) summarizing key take home contents delivered at the session.
Phase 2: Structured Preoperative Sedentary Behavior Reduction Program (T0 to T1) Participants will be asked to engage in the SBRPro, which includes aerobic and strength activities, in compliance with current PA guidelines. Flexibility to adapt the PA and exercise modality, duration, and intensity based on individual preferences, physical capacity, and available resources (home-based, gym-based, online platforms, or combined approaches) will be provided.
Phase 3: Structured Postoperative Sedentary Behavior Reduction Program (T2 to T4) Participants will be asked to resume SBRPro activities within the first week post-BS, adjusting the program for postoperative individual restrictions. A progressive increase in daily PA will be encouraged. For resistance exercises, participants will be advised to avoid heavy loading of incision/staple lines and to progress from light to moderate resistance as tolerated. Given the postoperative vulnerability, remote counseling will be provided as needed to enhance safety. The same weekly PA diary-based monitoring will be requested.
Physical Activity Monitoring and Adherence Assessment SBRPro adherence will be assessed through a structured weekly PA diary using a simple online form. The form will collect self-reported data on average daily sedentary time (minutes per day), total time spent in light, moderate, and vigorous physical activity (minutes per week), and the number of days per week engaged in resistance training. The form will also include a subsection addressing PA satisfaction/enjoyment (5-point Likert scale: 1, nothing fun; 2, little fun; 3, indifferent; 4, fun; 5, very fun), and any barriers or adverse events encountered. This weekly assessment will take place from baseline (the moment of enrolment in the study) until up to 12 months after surgery. For primary analyses, adherence subgroups, determined from the weekly PA diary, will be classified as having either an active or a sedentary lifestyle according to the most recent World Health Organization criteria. Individuals will be classified as physically active if they accumulate at least 150 minutes of moderate-intensity physical activity per week, and as sedentary if they do not meet this threshold. Participants with a sedentary lifestyle will serve as the de facto comparison group. This will enable evaluation of whether differential engagement with the SBRPro is associated with distinct clinical and functional outcomes.
- Clinical and Functional Assessments PF evaluations that include changes in body composition, muscle strength, and CRF will be assessed to determine the effects of the SBRPro. Body composition [total weight (kg) and weight loss (absolute and % excess weight lost), fat mass (kg and %), lean mass (kg and %), muscle mass (kg and %)] will be measured via bioimpedance analysis (InBody 970 model, Biospace, Korea). Muscle strength (Kgf) will be assessed using handgrip (Jamar+, Lafayette Instrument Company, USA) and knee isometric strength tests (GripWise, Wisify Tech Solutions, Lda., Portugal). The estimated CRF (eVO2m) will be evaluated using the 2-minute step test (2MST). Changes in PA patterns between T0 and T1, and T2 and T3 will be subjectively measured using the language validated 24-hour movement questionnaire (QMov24h) and objectively measured PA, between T1 and T2, via accelerometry (ActiGraph wGT3X-BT model, Ametrics, USA), worn for 7 days, quantifying daily activity volume (steps, minutes of light, moderate, and vigorous activity), and sedentary time. The resolution or improvement of the ORCD and the health-related QoL will be assessed using the SF-12 (12-item Short Form Health Survey) validated questionnaire.
- Biological Sampling and Molecular Analyses Fasting blood samples will be collected at T0, T1, and T3. Plasma will be processed and stored at -80ºC for metabolomic profiling. Circulating metabolomic profiling will be performed using proton nuclear magnetic resonance (1H-NMR) spectroscopy to evaluate longitudinal systemic metabolic adaptations across time points. Molecular findings will subsequently be integrated with clinical and functional outcomes to explore potential mechanistic links between behavioral modification, tissue remodeling, and postoperative results.
During BS (T2), biopsies of abdominal skeletal muscle (transversus abdominis) and visceral adipose tissue (VAT) will be obtained under direct surgical visualization. Tissue fragments will be immediately processed and preserved at -80ºC for downstream proteomic analysis. Label-free quantitative proteomics, using the GeLC MS/MS approach, will be performed to identify differential protein expression patterns between adherence groups. Functional enrichment and pathway analyses will be conducted to characterize biological processes associated with preoperative SB reduction and PA engagement.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Adherent group | Experimental | Behavioral: Sedentary behavior reduction program on physical fitness.Participants will be instructed in the sedentary behavior reduction program (SBRPro) and asked to maintain weekly physical activity diaries throughout the pre- and post-operative periods. |
| Non-adherent group | No intervention | –Non-adherence to the sedentary behavior reduction program. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adult women (≥ 18 years);
- BMI of 30-45 kg/m2;
- Scheduled for primary vertical sleeve gastrectomy or Roux-en-Y gastric bypass;
- Capacity to provide informed consent, adequate proficiency in the national language;
- Access to the internet and mobile phone communication.
Key exclusion criteria (5 listed)
- Previous bariatric surgery or gastric surgical procedure;
- Physical incapacity or medical contraindications precluding physical fitness testing or participation (active cardiac disease, uncontrolled hypertension, severe joint disease);
- Pregnancy or breastfeeding;
- Inability to provide informed consent or comply with study procedures;
- Patients with type 1 or 2 diabetes mellitus.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sedentary behavior reduction program on physical fitness.The BARIMOV protocol incorporates this evidence through a structured, online sedentary behavior reduction program (SBRPro) that emphasizes substituting sedentary behavior with physical activity throughout the day. | Behavioural | Adherent group |
Primary outcome
Percentage of total weight loss (%TWL)
Time frame: Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Primary clinical outcome evaluating the percentage of total weight loss, measuring weight in kilograms before and after surgery.
Obesity-related complications and diseases (ORCD)
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Pre- and post-operative status comparison through in-person clinical evaluations and routine laboratory analyses, including physical examination findings and longitudinal changes in pharmacological treatment requirements. ORCD will be assessed as a composite outcome including the presence of the following conditions, defined using a standardized criterion: Type 2 diabetes mellitus: HbA1c≥6.5% or use of glucose-lowering medication; Hypertension: systolic BP≥140 mmHg, diastolic BP≥90 mmHg, or antihypertensive treatment; Dyslipidemia: LDL-C, HDL-C, or triglycerides outside guideline thresholds or lipid-lowering therapy; Obstructive sleep apnea: confirmed by polysomnography [AHI≥5 events/hour]; Gastroesophageal reflux disease (GERD): heartburn and/or acid regurgitation occurring≥2 times per week or current use of proton pump inhibitors (PPIs) for reflux symptoms with prior physician diagnosis of GERD; Metabolic syndrome: defined according to NCEP ATP ΙΙΙ criteria.
Changes in health-related quality of life (QoL)
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Primary clinical outcome assessed by using the SF-12 (12-item Short Form Health Survey), a validated questionnaire.
5 secondary outcomes
Body composition
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Muscle strength
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Cardiorespiratory fitness (CRF)
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Identification of proteomic differences in skeletal muscle and visceral adipose tissue associated with adherence at the time of surgery
Time frame: Intra-operative: T2
Longitudinal blood metabolomic adaptations
Time frame: Preoperative assessments: T0 (6±3 months before surgery), and T1 (2 weeks±3 days before surgery). Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
Related trials for Obesity (Disorder)
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sedentary behavior reduction program on physical fitness. in people with Obesity (Disorder), run by Hospital de Sao Sebastiao at 1 site in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Unidade Local de Saúde Entre Douro e Vouga (+351 256 379 700, geral@ulsedv.min-saude.pt), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of total weight loss (%TWL) (time frame: Postoperative reassessment: T3 (3±1 months after surgery) and T4 (12±2 months after surgery).). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.